Biology of Fibroblast Growth Factor 23: From Physiology to Pathology

Courbebaisse, Marie; Lanske, Beate

doi:10.1101/cshperspect.a031260

Cited by 56 publications

(50 citation statements)

References 156 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Vitamin D is activated by renal 1α-hydroxylase and is responsible for maintaining calcium-phosphate homeostasis by increasing calcium and phosphate absorption. Patients with CKD are affected by vitamin D deficiency, which has even been reported after successful kidney transplantation (Ewers et al 2008). Low levels of vitamin D in hemodialyzed patients were reported to be associated with obesity and metabolic syndrome (Ahmadi et al 2016).…”

Section: Introductionmentioning

confidence: 99%

Bone Metabolism Parameters in Hemodialysis Patients With Chronic Kidney Disease and in Patients After Kidney Transplantation

Marchelek-Myśliwiec¹,

Dziedziejko²,

Nowosiad-Magda³

et al. 2019

Physiol Res

View full text Add to dashboard Cite

Chronic kidney disease adversely affects the structure and metabolism of bone tissue, which may be a result of disturbed biochemical processes in adipose tissue. Renal replacement therapy is a life-saving therapy but it does not restore all metabolic functions and sometimes even escalates some disturbances. The study included 126 subjects: 47 hemodialysis patients (HD), 56 patients after renal transplantation (Tx) and 23 healthy controls (K). Bone density at the femoral neck (FN) and lumbar spine (LS), as well as body composition (adipose tissue content and lean body mass) were measured in each patient using the DXA method. In addition, serum concentrations of glucose, calcium, phosphorus, parathormone, FGF23, Klotho, osteocalcin, leptin, adiponectin and 1,25-dihydroxyvitamin D3 were measured. We observed significantly higher concentrations of leptin, FGF23 and Klotho proteins in the HD patients (77.2±48.1 ng/ml, 54.7±12.4 pg/ml, 420.6±303.8 ng/ml, respectively) and the Tx group (33.2±26.5 ng/ml; 179.8±383.9 pg/ml; 585.4±565.7, respectively) compared to the control group (24.4±24.6 ng/ml, 43.3±37.3 pg/ml, 280.5± 376.0 ng/ml). Significantly lower bone density at FN was observed in the HD and Tx patients in comparison to the controls and in the HD patients compared to the Tx group. There were no significant differences in body mass composition between the studied groups. The results of this study indicate that both hemodialysis and transplantation are associated with increased serum concentrations of leptin, FGF23 and Klotho proteins, as well as lower bone density at femoral neck.

show abstract

Section: Introductionmentioning

confidence: 99%

Bone Metabolism Parameters in Hemodialysis Patients With Chronic Kidney Disease and in Patients After Kidney Transplantation

Marchelek-Myśliwiec¹,

Dziedziejko²,

Nowosiad-Magda³

et al. 2019

Physiol Res

View full text Add to dashboard Cite

show abstract

“…Hypophosphatemia is not infrequent in the following days after FCM infusion [115], with a mechanism that appears peculiar to its unique carbohydrate moiety [116]. Indeed, FCM is able to induce the synthesis of fibroblast growth factor 23 (FGF-23), an osteocyte-derived hormone that regulates phosphate and vitamin D homeostasis [117], ultimately leading to increased renal excretion of phosphate [115]. However, FCM-induced hypophosphatemia does not appear clinically meaningful, as it is mild, transient, and without symptoms or sequelae.…”

Section: The Newer IV Iron Preparationsmentioning

confidence: 99%

Modern iron replacement therapy: clinical and pathophysiological insights

et al. 2017

View full text Add to dashboard Cite

Iron deficiency, with or without anemia, is extremely frequent worldwide, representing a major public health problem. Iron replacement therapy dates back to the seventeenth century, and has progressed relatively slowly until recently. Both oral and intravenous traditional iron formulations are known to be far from ideal, mainly because of tolerability and safety issues, respectively. At the beginning of this century, the discovery of hepcidin/ferroportin axis has represented a turning point in the knowledge of the pathophysiology of iron metabolism disorders, ushering a new era. In the meantime, advances in the pharmaceutical technologies are producing newer iron formulations aimed at minimizing the problems inherent with traditional approaches. The pharmacokinetic of oral and parenteral iron is substantially different, and diversities have become even clearer in light of the hepcidin master role in regulating systemic iron homeostasis. Here we review how iron therapy is changing because of such important advances in both pathophysiology and pharmacology.

show abstract

“…Calcitriol promotes bone formation and growth, by activating chondrocyte differentiation, and increasing serum calcium and phosphate levels. Thus, vitamin D deficiency results in inadequate mineralization of the skeleton, and when low vitamin D levels are maintained, bone growth plates cannot be mineralized due to calcium and phosphate depletion [22,23].…”

Section: Regulation Of Vitamin D Metabolismmentioning

confidence: 99%

Vitamin D: Classic and Novel Actions

2018

View full text Add to dashboard Cite

Background: Classically, vitamin D has been implicated in bone health by promoting calcium absorption in the gut and maintenance of serum calcium and phosphate concentrations, as well as by its action on bone growth and reorganization through the action of osteoblasts and osteoclasts cells. However, in the last 2 decades, novel actions of vitamin D have been discovered. The present report summarizes both classic and novel actions of vitamin D. Summary: 1,25(OH)₂ vitamin D, the active metabolite of vitamin D, also known as calcitriol, regulates not only calcium and phosphate homeostasis but also cell proliferation and differentiation, and has a key a role to play in the responses of the immune and nervous systems. Current effects of vitamin D include xenobiotic detoxification, oxidative stress reduction, neuroprotective functions, antimicrobial defense, immunoregulation, anti-inflammatory/anticancer actions, and cardiovascular benefits. The mechanism of action of calcitriol is mediated by the vitamin D receptor, a subfamily of nuclear receptors that act as transcription factors into the target cells after forming a heterodimer with the retinoid X receptor. This kind of receptors has been found in virtually all cell types, which may explain its multiple actions on different tissues. Key Messages: In addition to classic actions related to mineral homeostasis, vitamin D has novel actions in cell proliferation and differentiation, regulation of the innate and adaptative immune systems, preventive effects on cardiovascular and neurodegenerative diseases, and even antiaging effects.

show abstract

Biology of Fibroblast Growth Factor 23: From Physiology to Pathology

Cited by 56 publications

References 156 publications

Bone Metabolism Parameters in Hemodialysis Patients With Chronic Kidney Disease and in Patients After Kidney Transplantation

Bone Metabolism Parameters in Hemodialysis Patients With Chronic Kidney Disease and in Patients After Kidney Transplantation

Modern iron replacement therapy: clinical and pathophysiological insights

Vitamin D: Classic and Novel Actions

Contact Info

Product

Resources

About